Jakafi

{
  "id": "MLC-T-ONC-004570",
  "term": "Jakafi",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults with certain types of primary myelofibrosis (MF), post-polycythemia vera MF, post-essential thrombocythemia MF, or polycythemia vera, and adults and children aged 12 years and older with acute or chronic graft-versus-host disease. It is also being studied in the treatment of some types of cancer. Jakafi blocks a protein called JAK, which may help keep abnormal blood cells or cancer cells from growing. It may also lower the body’s immune response. Jakafi is a type of tyrosine kinase inhibitor. Also called ruxolitinib phosphate.",
  "synonyms": [
    "ruxolitinib phosphate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/jakafi/"
}